Citius Pharmaceuticals (CTXR) Receivables - Other (2018)
Citius Pharmaceuticals' (CTXR) quarterly Receivables - Other came in at -$818343.0 in Q4 2018, down 200.0% quarter-over-quarter from $818343.0 in Q3 2018.
Powered by 
Analysis
Citius Pharmaceuticals (CTXR) Receivables - Other (2018) Analysis & Trends
Citius Pharmaceuticals (CTXR) has reported Receivables - Other for 1 consecutive years, with -$818343.0 the latest figure, recorded in Q4 2018.
- For the quarter ending Q4 2018, Receivables - Other changed N/A year-over-year to -$818343.0; the trailing twelve-month figure through Sep 2019 stood at -$818343.0 (down 200.0% YoY), and the FY2019 full-year result was -$818343.0, down 200.0% from the prior year.
- Receivables - Other slipped to -$818343.0 in Q4 2018 per CTXR's latest filing, from $818343.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $818343.0 in Q3 2018 and bottomed at -$818343.0 in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.22 Bn | 620.47 Bn | 17.26 Bn |
| 2 | AbbVie | 446.28 Bn | 439.71 Bn | 12.70 Bn |
| 3 | Merck | 357.56 Bn | 350.42 Bn | 12.21 Bn |
| 4 | Novartis Ag | 268.11 Bn | 260.42 Bn | 11.24 Bn |
| 5 | Pfizer | 156.86 Bn | 145.17 Bn | 10.94 Bn |
| 6 | Sanofi | 52.10 Bn | 44.72 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.01 Bn | 43.01 Bn | - |
| 8 | Incyte | 24.82 Bn | 20.28 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.39 Bn | 18.73 Bn | 683.80 Mn |
| 10 | Citius Pharmaceuticals | 15.27 Mn | 15.27 Mn | 1.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | -818,343.00 |
| Sep 30, 2018 | 818,343.00 |